Standard treatment
Chemotherapy
Systemic cytotoxic drugs that act on rapidly dividing cells, given in scheduled cycles.

Not a diagnosis and not final medical advice. Must be reviewed by a doctor.
What is it?
Chemotherapy can be given alone or with targeted therapy and immunotherapy.
Administration is carried out in cycles, with breaks for the body to recover between cycles.
The regimen and number of cycles vary according to the type of cancer, goals, and patient condition.
The drug enters the bloodstream and affects cells that are dividing, including cancer cells and some normal cells that change quickly.
How it works
The drug enters the bloodstream and affects cells that are dividing, including cancer cells and some normal cells that change quickly.
Position in the treatment pathway: Can be main therapy, precursor therapy before surgery, therapy after surgery, or palliative therapy.

Which cancers is it usually discussed for?

Stomach Cancer
Stomach cancer is most often adenocarcinoma, and HER2, PD-L1, MSI/MMR and CLDN18.2 status can change which treatment options are discussed.
Open cancer page
Lung Cancer
Lung cancer is divided into non-small-cell and small-cell groups, and molecular markers strongly shape which treatment options are discussed.
Open cancer page
Lymphoma
Lymphoma is a malignancy of the lymphatic system with many subtypes, and accurate pathological classification determines the direction of treatment.
Open cancer page
Multiple Myeloma
Multiple myeloma is a malignancy of plasma cells in the bone marrow, with cytogenetic markers that matter when treatment strategy is considered.
Open cancer page
Usually considered
- Adequate blood condition and organ function.
- Suitability of therapeutic goals to disease conditions.
Usually not a candidate
- General conditions or organ function that do not allow drug administration.
- History of severe reactions to certain medications.
What is the process like?
Preparation 1
Blood examination.
Preparation 2
Evaluation of organ function.
Preparation 3
Adjustment of medications and anti-nausea plans.
Monitoring
Periodic blood tests.
All preparation
- Blood examination.
- Evaluation of organ function.
- Adjustment of medications and anti-nausea plans.
All monitoring
- Periodic blood tests.
- Assessment of side effects before each cycle.
Risks and points to watch
Side-effect notes, not a complete list
- Nausea, fatigue, decreased blood cells, mouth sores, and hair loss may appear.
- Some side effects are temporary and can be managed.
- Some long-term effects depend on the drug used.
Cost and access
Cost figures depend heavily on location, facility and payer. We do not show estimated figures on this page; what can be prepared first are the questions.
Cisplatin
Platinum group cytotoxic
- Availability may vary between health facilities and changes over time.
- Funding pathway (insurance, patient access program, or self-directed) needs to be confirmed.
- Prices are not listed because they cannot be verified responsibly.
Capecitabine
Oral antimetabolites
- Availability may vary between health facilities and changes over time.
- Funding pathway (insurance, patient access program, or self-directed) needs to be confirmed.
- Prices are not listed because they cannot be verified responsibly.
Oxaliplatin
Platinum group cytotoxic
- Availability may vary between health facilities and changes over time.
- Funding pathway (insurance, patient access program, or self-directed) needs to be confirmed.
- Prices are not listed because they cannot be verified responsibly.
Trastuzumab deruxtecan
Anti-HER2 antibody-drug conjugate
- Availability may vary between health facilities and changes over time.
- Funding pathway (insurance, patient access program, or self-directed) needs to be confirmed.
- Prices are not listed because they cannot be verified responsibly.
Providers and clinical trials
Access status not yet verified
NCT04267848Phase 3Immunotherapy
Testing the Addition of a Type of Drug Called Immunotherapy to the Usual Chemotherapy Treatment for Non-small Cell Lung Cancer, an ALCHEMIST Treatment Trial (Chemo-IO [ACCIO])
Lung Cancer | Immunotherapy, Chemotherapy
United States, Guam1151 registry sites
Why this appears: Appears because it is recorded for Lung Cancer, the treatment category is Immunotherapy.
What to verify: Acceptance of patients from outside the local country has not been verified.
- Registry
- Recruiting in registry
- Site
- Not verified
- International access
- Unknown
- Patient match
- Not assessed
Last checked 16 Oktober 2026Source ClinicalTrials.govNCT04267848Not verified
NCT04301076Phase 1Diagnostics and monitoring
Testing the Addition of an Anti-cancer Drug, Lenalidomide, to the Usual Combination Chemotherapy Treatment ("EPOCH") for Adult T-Cell Leukemia-Lymphoma (ATLL)
United States19 registry sites
Why this appears: Appears because it is recorded for Lymphoma, the treatment category is Chemotherapy.
What to verify: Acceptance of patients from outside the local country has not been verified.
- Registry
- Recruiting in registry
- Site
- Not verified
- International access
- Unknown
- Patient match
- Not assessed
Last checked 16 Oktober 2026Source ClinicalTrials.govNCT04301076Not verified
NCT05139017Phase 2 / Phase 3Immunotherapy
A Study of Zilovertamab Vedotin (MK-2140) in Combination With Standard of Care in Participants With Relapsed or Refractory Diffuse Large B-Cell Lymphoma (rrDLBCL) (MK-2140-003)
Lymphoma | Immunotherapy, Chemotherapy
United States, Argentina, Australia +23135 registry sites
Why this appears: Appears because it is recorded for Lymphoma, the treatment category is Immunotherapy.
What to verify: Acceptance of patients from outside the local country has not been verified.
- Registry
- Recruiting in registry
- Site
- Not verified
- International access
- Unknown
- Patient match
- Not assessed
Last checked 16 Oktober 2026Source ClinicalTrials.govNCT05139017Not verified
NCT05633615Phase 2CAR-T cell therapy
Testing Drug Treatments After CAR T-cell Therapy in Patients With Relapsed/Refractory Diffuse Large B-cell Lymphoma
Lymphoma | biomarker: CD19 | CAR-T cell therapy, Immunotherapy, Chemotherapy
United States95 registry sites
Why this appears: Appears because it is recorded for Lymphoma, it mentions marker CD19, the treatment category is CAR-T cell therapy.
What to verify: Acceptance of patients from outside the local country has not been verified.
- Registry
- Recruiting in registry
- Site
- Not verified
- International access
- Unknown
- Patient match
- Not assessed
Last checked 16 Oktober 2026Source ClinicalTrials.govNCT05633615Not verified
NCT05675410Phase 3Combination regimen
A Study to Compare Standard Therapy to Treat Hodgkin Lymphoma to the Use of Two Drugs, Brentuximab Vedotin and Nivolumab
Lymphoma | Immunotherapy, Radiotherapy, Chemotherapy
United States, Canada, Puerto Rico417 registry sites
Why this appears: Appears because it is recorded for Lymphoma, the treatment category is Immunotherapy.
What to verify: Acceptance of patients from outside the local country has not been verified.
- Registry
- Recruiting in registry
- Site
- Not verified
- International access
- Unknown
- Patient match
- Not assessed
Last checked 16 Oktober 2026Source ClinicalTrials.govNCT05675410Not verified
NCT06124157Phase 2Combination regimen
A Study Testing the Combination of Dasatinib or Imatinib to Chemotherapy Treatment With Blinatumomab for Children, Adolescents, and Young Adults With Philadelphia Chromosome Positive (Ph+) or ABL-Class Philadelphia Chromosome-Like (Ph-Like) B-cell Acute Lymphoblastic Leukemia (B-ALL)
Lymphoma | Targeted therapy, Radiotherapy, Chemotherapy
United States, Australia, Canada +1159 registry sites
Why this appears: Appears because it is recorded for Lymphoma, the treatment category is Targeted therapy.
What to verify: Acceptance of patients from outside the local country has not been verified.
- Registry
- Recruiting in registry
- Site
- Not verified
- International access
- Unknown
- Patient match
- Not assessed
Last checked 16 Oktober 2026Source ClinicalTrials.govNCT06124157Not verified
Questions for the doctor
- What is the aim of this chemotherapy and how will success be assessed?
- Which side effects need to be reported immediately?
- What can be done to reduce side effects?
Sources
- NCI Dictionary of Cancer Terms(lembaga)
Is Chemotherapy relevant for my case?
Ask for an initial review. We will explain which documents and markers need to be completed before discussion with a doctor.
Upload reports
Photos or PDFs of pathology, biomarkers, imaging and treatment history.
Case structured
Documents are turned into a structured case summary.
Navigator review
A human navigator checks completeness before anything is shared.
Provider review
With your consent, the case is discussed with providers for assessment and a written quote.
Is Chemotherapy relevant for my case?
Ask for an initial review. We will explain which documents and markers need to be completed before discussion with a doctor.
After submission, a human navigator reviews your request and contacts you through your chosen channel. The WhatsApp message already includes this page context, so you do not need to explain from the beginning.
Clinical data is not requested in the form and is not sent to analytics. Do not send medical reports through WhatsApp or email; use the secure upload page. We do not promise eligibility or any treatment outcome.
You just read about Chemotherapy. Next:

DLBCL kambuh? Kapan terapi CAR-T mulai dibahas
9 min read
Kemoterapi tidak bekerja: langkah berikutnya apa yang perlu ditanyakan?
5 min read

Clinical trials mentioning this category
68 public registry records mention this category.

Upload Medical Reports
Find out whether this category is worth asking about for your case, using structured documents.
Next steps
These suggestions come from links between entries in TanyaKanker's database, not from a medical judgement. Each suggestion includes why it appears.
Next to learn
- CD20
Biomarker
Reason: Related through a biomarker
- MGMT
Biomarker
Reason: Related through a biomarker
- Bortezomib
Drug
Reason: Uses this drug
- Capecitabine
Drug
Reason: Uses this drug
- onkologi-medis
Service
Reason: Related to this page
- CLDN18.2: China approved zolbetuximab for first line care - what it means for Indonesian patients
Explainer
Reason: Related to this page
To check
- Echocardiography
Diagnostic test
Reason: Memerlukan pemeriksaan
- Blood laboratory tests
Diagnostic test
Reason: Memerlukan pemeriksaan
- Gastric cancer after chemotherapy no longer gives results
Decision situation
Reason: Mungkin memerlukan
- Newly diagnosed lung cancer
Decision situation
Reason: Mungkin memerlukan
- Lung cancer that is still operable
Decision situation
Reason: Mungkin memerlukan
- Locally advanced lung cancer
Decision situation
Reason: Mungkin memerlukan
What you can do
- Upload medical reports
Build a case summary in twelve steps
Reason: Often the most useful next step after reading this page
- Request a second opinion
Review of the treatment plan
Reason: Relevant when a treatment plan is being considered
- Consult a navigator
A request is recorded with this page context
Reason: For asking the next step directly
Recently updated
- Leukemia
Cancer page
Date: Data revision 2026-09-10
- Brain Cancer
Cancer page
Date: Data revision 2026-09-10
- Pancreatic Cancer
Cancer page
Date: Data revision 2026-09-10
- Testing Osimertinib as a Treatment for Lung Cancers With an EGFR Exon 20 Change
NCT03191149 - Phase 2
Date: Registry update in the last 30 days (2026-10-15)
Want to follow changes on this topic? Save the page or follow the topic so it is easy to find again. View saved items.
Prepare for your next consultation
Use the free six-question tool to prepare questions for your doctor.

